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A 78-year-old  male  presented  to  the  emergency  depart-
ent  (ER)  with  hematemesis.  Two  weeks  earlier,  he
erformed  a  gastroscopy  for  dyspepsia  that  showed  an
rregular  convex  deformity  in  greater  curvature  of  the  gas-
ric  body  covered  by  congestive  and  ulcerated  mucosa.
iopsies  were  diagnostic  of  a  gastric  gastrointestinal  stromal
umor  (GIST):  fusocellular  neoplasm  with  increased  cellular-
ty  and  marked  pleomorphism,  with  immunohistochemical
taining  positive  for  CD117  and  negative  for  smooth  muscle
ctin,  desmin  and  S100.  CT  scan  conﬁrmed  an  exophitic  gas-
ric  tumor  and  showed  multiple  endoperitoneal  locations.
e  started  treatment  at  that  time  with  imatinib-mesylate
00  mg  daily.∗ Corresponding author.
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Hb  9.7  g/dL)  with  a  white  blood  cell  count  of  21.200/mm3
neutrophil  count  19.400/mm3),  CRP  72.2  mg/L  (normal
alue  <  5.0  mg/L)  and  lactate  dehydrogenase  380  U/L  (nor-
al  value  <248  U/L).  Upper  endoscopy  again  showed  the
bovementioned  irregular  deformity  covered  by  irregular
ucosa  in  the  gastric  body.  It  now  had  an  oriﬁce  of  about
5  mm  in  diameter,  which  allowed  the  passage  of  the  endo-
cope  to  a  cavity  with  abundant  exudate  and  necrotic  debris
Fig.  1).  No  signiﬁcant  changes  were  noted  in  the  remainder
arts  of  the  stomach,  the  esophagus  and  the  duodenum.  No
lood  was  observed.
Contrast-enhanced  CT  scan  showed  a  9 cm  ×  12  cm  ×
0  cm  exophytic  gastric  tumor  with  central  necrosis  arising
rom  posterior  wall  of  the  gastric  body.  It  was  possible  to
ee  contrast  leaks  from  the  stomach  communicating  with
he  cavities;  there  were  neither  ﬂuid  levels  nor  pneumoperi-
oneum  (Fig.  2).
The  patient  was  admitted  for  recovery  and  no  recurrence
f  bleeding  was  noted.  The  multidisciplinar  team  (encom-
assing  oncologists  and  surgeons)  decided  to  stop  imatinib
nd  provide  the  best  supportive  care  for  the  patient,  who
ied  one  month  later.
GISTs  account  for  approximately  1--3%  of  all  the  gas-
rointestinal  tract  neoplasms  with  a  malignant  potential  of
0--30%.1 Of  all  GISTs  in  the  gastrointestinal  tract,  50--60%
ccur  in  the  stomach.2 Imatinib  has  become  the  standard
reatment  for  metastatic  GISTs.  Exposure  of  GIST  cells  to
matinib,  arrests  cell  proliferation,  and  causes  apoptotic  cell
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Figure  1  The  oriﬁce  in  the  gastric  body  (A)  allowing  the  passage
Figure  2  Axial  CT  after  iodine  injection  and  oral  contrast.
The image  depicts  a  large  exophitic  tumor  (arrows)  arising  from
the posterior  wall  of  the  stomach  (star).  The  tumor  has  cen-
tral necrosis  shown  by  a  contrast-ﬂuid  level  (curved-arrow).
Oral contrast  ﬂowing  from  the  stomach  into  the  tumor  cavity
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death.  Because  of  the  massive  cytolytic  effect  of  the  drug,
when  treatment  is  given  for  GISTs  located  in  the  wall  of  the
gastrointestinal  tract  not  only  gastrointestinal  hemorrhage
but  also  ulceration,  cavitation,  ﬁstulization  and  perforation
can  occur  due  to  massive  necrosis  of  the  tumour.3 The  last
complications  are  often  ﬁrst  seen  at  imaging  performed  for
assessment  of  tumor  response  to  imatinib.  However,  gas-
troenterologists  should  be  aware  of  such  adverse  events  as
3 of  the  endoscope  to  a  cavity  ﬁlled  with  necrotic  debris  (B).
hese  may  be  observed  on  the  course  of  endoscopic  proce-
ures.
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